Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.
By J. Rowe, G. Buck, A. Burnett, R. Chopra, P. Wiernik, S. Richards, H. Lazarus, I. Franklin, M. Litzow, N. Ciobanu and 4 more. Blood, 2005
677 citations recorded by the source corpus.
Subfields: Hematology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/6f9b162063945529af34095e6d85ff1f68982818
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Litzow
Citations in the corpus
- Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. (2007, background): “Research Council of the United Kingdom Adult ALL Working Party and the Eastern Cooperative Oncology Group From:.(1)Royal Free and University College London Medical School, London, UK; (2)Clinical Trial Service Unit, Oxford, UK; (3)Christie Hospital NHS Trust, Manchester, UK; (current address: Astra ”
- Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. (2005, neutral): “Other MLL/11q23 translocations 29 (9-52) 1.”